Real-World Outcomes of Adjuvant Paclitaxel and Trastuzumab Therapy in Lymph Node-Negative, HER2-Positive Early-Stage Breast Cancer: A Multicenter Retrospective Data Analysis.

Cancers (Basel) · 2025 · PMC12293757 · PMID 40723155

Europe PMC DOI

hedged sentence

0.2460

closest p · 4.9× alpha

0.2460

boldest claim

The sentences

did not reach statistical significancep = 0.246not close (p > 0.1)

Additionally, patients who experienced neuropathy during treatment showed a higher 5-year RFS (98.5%) compared to those without neuropathy (94.8%), though this difference did not reach statistical significance ( p = 0.246, Figure 4 ). 3.3.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.